Trials / Not Yet Recruiting
Not Yet RecruitingNCT07375524
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of ESG206 in participants with primary Sjögren's syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ESG206 | ESG206 Low Dose administered by intravenous infusion |
| DRUG | ESG206 | ESG206 High Dose administered by intravenous infusion |
| DRUG | Placebo | Placebo administered by intravenous infusion |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2027-12-31
- Completion
- 2028-06-30
- First posted
- 2026-01-29
- Last updated
- 2026-02-03
Locations
21 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07375524. Inclusion in this directory is not an endorsement.